相关实验视频

Updated: Aug 27, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

PD-1-cis IL-2R 激动因子从类似干细胞的 CD8⁺ T 细胞产生更好的效应因子

Laura Codarri Deak¹, Valeria Nicolini¹, Masao Hashimoto²

¹Roche Innovation Center Zurich, Schlieren, Switzerland.

|September 28, 2022

概括

一种新型免疫细胞因子PD1- IL2v有效地将类似干细胞的CD8+ T细胞分化为无CD25结合的强效效应细胞. 这种方法通过避免不必要的副作用来增强癌症和慢性感染的免疫疗法.

科学领域:

免疫学
癌症生物学
病毒学

背景情况:

抗原经验的PD-1+TCF-1+类干细胞对PD-1阻断免疫疗法的成功至关重要.
互白素 (IL) - 2促进干状T细胞分化为"更好的效应"CD8+T细胞,但CD25结合会引起全身性影响.
设计的IL-2受体β和γ链 (IL-2Rβγ) 偏差激剂旨在减轻这些副作用.

研究的目的:

在癌症模型中评估IL-2Rβγ偏差激素扩大"更好的效应"T细胞.
引入PD1-IL2v,一种旨在向PD-1和IL-2Rβγ的新型免疫细胞因子.
评估PD1-IL2v在分化类似干细胞的CD8+T细胞和治疗慢性感染和癌症方面的有效性.

主要方法:

开发和测试PD1-IL2v,一种针对PD-1的IL-2变种.
在慢性感染和癌症模型中评估T细胞分化和扩张.
将PD1-IL2v与PD-1/PD-L1阻断抗体和非向IL-2变体进行比较.

主要成果:

在癌症模型中,IL-2Rβγ偏差激剂未能优先扩大"更好的效应者"T细胞.
在没有 CD25 结合的情况下,PD1- IL2v 成功将类似干细胞的 CD8+ T 细胞分化为"更好的效应细胞",在慢性感染和癌症模型中显示出更高的疗效.
与非向IL-2变异的PD-1/ PD- L1阻塞导致了耗尽的T细胞积累,与PD1- IL2v不同.

结论:

PD1-IL2v克服了CD25的依赖性,使得"更好的效应者"CD8+T细胞能够有针对性的扩张.
这一新一代的PD- 1 cis向IL- 2R激动剂为癌症和慢性感染提供了增强的治疗潜力.
通过产生有效的抗瘤和抗病毒T细胞反应,PD1- IL2v是改善免疫治疗结果的有希望的策略.

更多相关视频

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

相关概念视频

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.